The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy.

@article{Bien2007TheER,
  title={The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy.},
  author={Sandra Bien and A. R. Riad and Christoph Alexander Ritter and Matthias Gratz and Florian Olshausen and Dirk Westermann and Markus Grube and Thomas Krieg and Sabine Ciecholewski and Stephan Burkhart Felix and Alexander Staudt and Heinz-Peter Schultheiss and Ralf Ewert and Uwe Voelker and Carsten Tsch{\"o}pe and Heyo Klaus Kroemer},
  journal={Cancer research},
  year={2007},
  volume={67 21},
  pages={10428-35}
}
Doxorubicin is a frequently used anticancer drug, but its therapeutic benefit is limited by acute and chronic cardiotoxicity, often leading to heart failure. The mechanisms underlying doxorubicin-induced cardiotoxicity remain unclear. It was previously shown in men that doxorubicin leads to increased endothelin-1 plasma levels. In addition, cardiac-specific overexpression of endothelin-1 in mice resulted in a cardiomyopathy resembling the phenotype following doxorubicin administration. We… CONTINUE READING
30 Citations
43 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Similar Papers

Loading similar papers…